Market interest in China's healthcare sector, particularly in innovative drugs, picked up strongly since April 2025, suggesting that the contract sales organization (CXO) sector will attract more attention ahead of the summer reporting season, with the leaders benefiting from improving fundamentals, attractive valuations and continued growth in order backlog, Citi Research issued a research report saying. The broker upgraded TIGERMED CONSULTING(300347.SZ) -0.660 (-1.152%) 's A-shares to Buy from Sell, as it believed that most of the leaders are trading at low prices. WUXI APPTEC (02359.HK) -0.150 (-0.168%) Short selling $13.90M; Ratio 8.921% (603259.SH) -1.270 (-1.586%) and WUXI BIO (02269.HK) 0.000 (0.000%) Short selling $124.55M; Ratio 19.465% are its top picks.Related NewsPing An Securities Recommends Eyeing 3 Key Themes amid Spreading 'Anti-Involution' RallyFor WUXI XDC (02268.HK) +0.100 (+0.205%) Short selling $4.99M; Ratio 5.173% , faster growth in undelivered orders could boost its 1H25 revenue beyond guidance.As for TIGERMED CONSULTING, Citi Research upgraded its A-share to Buy, meanwhile keeping rating at Buy on TIGERMED (03347.HK) -1.100 (-2.308%) Short selling $5.58M; Ratio 3.653% . The broker also lifted its target prices to RMB67/ $73 from RMB34/ $37, respectively.The table below shows Citi Research's assessment on related pharmaceutical companies:Related NewsNomura Mildly Cuts WUXI BIO's TP to HKD34.23, Rating BuyStock |Rating |TPAPPTEC(603259.SH) -1.270 (-1.586%) |Buy| RMB88WUXI BIO (02269.HK) 0.000 (0.000%) Short selling $124.55M; Ratio 19.465% |Buy|$35 TIGERMED (03347.HK) -1.100 (-2.308%) Short selling $5.58M; Ratio 3.653% |Buy|$73 WUXI XDC (02268.HK) +0.100 (+0.205%) Short selling $4.99M; Ratio 5.173% |Buy|$46 PHARMARON (03759.HK) -1.140 (-5.975%) Short selling $10.35M; Ratio 4.890% |Buy|$33(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-16 12:25.) (A Shares quote is delayed for at least 15 mins.)